Arwin Health is developing Fc-SPINK1, a first-in-class biologic designed to address the root cause of hereditary and genetic forms of pancreatitis.
We're a dedicated team of scientists and researchers committed to developing breakthrough therapies for patients with unmet medical needs.
Fc-SPINK1 represents a novel therapeutic approach, targeting the underlying genetic cause of pancreatitis with precision.
Our research is grounded in deep understanding of pancreatic biology and guided by the highest standards of scientific rigor.
Every decision we make is driven by our commitment to improving the lives of patients affected by genetic pancreatitis.
A novel approach to treating genetic pancreatitis by restoring the natural protective mechanisms of the pancreas.
Genetic pancreatitis, caused by mutations in genes like PRSS1, SPINK1, and CTRC, affects thousands of patients worldwide with no disease-modifying therapies currently available.
Our lead candidate, Fc-SPINK1, is an Fc-fusion protein designed to:
Interested in learning more about Arwin Health or exploring partnership opportunities? We'd love to hear from you.
hello@arwinhealth.com